{"id":48716,"date":"2021-12-20T12:02:47","date_gmt":"2021-12-20T12:02:47","guid":{"rendered":"https:\/\/dailysouthafrica.com\/?p=48716"},"modified":"2021-12-20T12:02:47","modified_gmt":"2021-12-20T12:02:47","slug":"lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine","status":"publish","type":"post","link":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/","title":{"rendered":"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE"},"content":{"rendered":"<div style=\"width: 75px;height: 75px;border-radius: 50%;background: url(https:\/\/nordot-res.cloudinary.com\/c_limit,w_200,h_200,f_auto,q_auto:eco\/ch\/units\/840710052963713024\/profile_1.png);background-position: center;background-size: cover;vertical-align: middle\"><\/div>\n<div style=\"margin-left: 5px;font-size: 14px;font-weight: bold;vertical-align: middle\">Published by <br \/>The Street<\/div>\n<div style=\"margin-top: 10px\"><\/div>\n<p>By PR Newswire PHILADELPHIA, Dec. 20, 2021 \/PRNewswire\/ &#8212; Lannett Company, Inc. (LCI) &#8211; Get Lannett Company, Inc. Report today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC). &#8220;This IND submission is a key milestone and brings us one step closer to bringing this critically important and more affordable biosimilar medicine to the large and grow&#8230;<!--more--><\/p>\n<p><a class=\"nordot-read-more \" target=\"_blank\" href=\"https:\/\/nordot.app\/845632767830392832?c=819177386184916992\" rel=\"noopener\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Published by The Street By PR Newswire PHILADELPHIA, Dec. 20, 2021 \/PRNewswire\/ &#8212; Lannett Company, Inc. (LCI) &#8211; Get Lannett Company, Inc. Report today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE&#8221;<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":48718,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE - Daily South Africa<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE - Daily South Africa\" \/>\n<meta property=\"og:description\" content=\"Published by The Street By PR Newswire PHILADELPHIA, Dec. 20, 2021 \/PRNewswire\/ &#8212; Lannett Company, Inc. (LCI) &#8211; Get Lannett Company, Inc. Report today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company &hellip; Continue reading &quot;LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/\" \/>\n<meta property=\"og:site_name\" content=\"Daily South Africa\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-20T12:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE\",\"datePublished\":\"2021-12-20T12:02:47+00:00\",\"dateModified\":\"2021-12-20T12:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/\"},\"wordCount\":111,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dailysouthafrica.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png\",\"articleSection\":[\"General\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/\",\"url\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/\",\"name\":\"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE - Daily South Africa\",\"isPartOf\":{\"@id\":\"https:\/\/dailysouthafrica.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png\",\"datePublished\":\"2021-12-20T12:02:47+00:00\",\"dateModified\":\"2021-12-20T12:02:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#primaryimage\",\"url\":\"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png\",\"contentUrl\":\"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dailysouthafrica.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dailysouthafrica.com\/#website\",\"url\":\"https:\/\/dailysouthafrica.com\/\",\"name\":\"Daily South Africa\",\"description\":\"Latest News From South Africa\",\"publisher\":{\"@id\":\"https:\/\/dailysouthafrica.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dailysouthafrica.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dailysouthafrica.com\/#organization\",\"name\":\"Daily South Africa\",\"url\":\"https:\/\/dailysouthafrica.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dailysouthafrica.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2022\/07\/cropped-8e3924cf-36ef-47fa-b41a-9c8c4f299cda_200x200-1-1.png\",\"contentUrl\":\"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2022\/07\/cropped-8e3924cf-36ef-47fa-b41a-9c8c4f299cda_200x200-1-1.png\",\"width\":200,\"height\":93,\"caption\":\"Daily South Africa\"},\"image\":{\"@id\":\"https:\/\/dailysouthafrica.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE - Daily South Africa","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/","og_locale":"en_US","og_type":"article","og_title":"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE - Daily South Africa","og_description":"Published by The Street By PR Newswire PHILADELPHIA, Dec. 20, 2021 \/PRNewswire\/ &#8212; Lannett Company, Inc. (LCI) &#8211; Get Lannett Company, Inc. Report today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company &hellip; Continue reading \"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE\"","og_url":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/","og_site_name":"Daily South Africa","article_published_time":"2021-12-20T12:02:47+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#article","isPartOf":{"@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/"},"author":{"name":"","@id":""},"headline":"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE","datePublished":"2021-12-20T12:02:47+00:00","dateModified":"2021-12-20T12:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/"},"wordCount":111,"commentCount":0,"publisher":{"@id":"https:\/\/dailysouthafrica.com\/#organization"},"image":{"@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#primaryimage"},"thumbnailUrl":"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png","articleSection":["General"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/","url":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/","name":"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE - Daily South Africa","isPartOf":{"@id":"https:\/\/dailysouthafrica.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#primaryimage"},"image":{"@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#primaryimage"},"thumbnailUrl":"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png","datePublished":"2021-12-20T12:02:47+00:00","dateModified":"2021-12-20T12:02:47+00:00","breadcrumb":{"@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#primaryimage","url":"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png","contentUrl":"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2021\/12\/48716-profile_1.png","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/dailysouthafrica.com\/lannett-announces-submission-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dailysouthafrica.com\/"},{"@type":"ListItem","position":2,"name":"LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE"}]},{"@type":"WebSite","@id":"https:\/\/dailysouthafrica.com\/#website","url":"https:\/\/dailysouthafrica.com\/","name":"Daily South Africa","description":"Latest News From South Africa","publisher":{"@id":"https:\/\/dailysouthafrica.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dailysouthafrica.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dailysouthafrica.com\/#organization","name":"Daily South Africa","url":"https:\/\/dailysouthafrica.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dailysouthafrica.com\/#\/schema\/logo\/image\/","url":"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2022\/07\/cropped-8e3924cf-36ef-47fa-b41a-9c8c4f299cda_200x200-1-1.png","contentUrl":"https:\/\/dailysouthafrica.com\/wp-content\/uploads\/2022\/07\/cropped-8e3924cf-36ef-47fa-b41a-9c8c4f299cda_200x200-1-1.png","width":200,"height":93,"caption":"Daily South Africa"},"image":{"@id":"https:\/\/dailysouthafrica.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/posts\/48716"}],"collection":[{"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/comments?post=48716"}],"version-history":[{"count":0,"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/posts\/48716\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/media\/48718"}],"wp:attachment":[{"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/media?parent=48716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/categories?post=48716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailysouthafrica.com\/wp-json\/wp\/v2\/tags?post=48716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}